kargaa

Let's Buy Some Phizer!

Long
BATS:PFE   Pfizer
Analysis of Pfizer Inc. (PFE) on NYSE (Monthly Timeframe)

The provided chart exhibits the long-term price movement of Pfizer Inc. on the New York Stock Exchange, with data captured on a monthly timeframe, extending over a period from roughly 2006 to the current date.

Observations:

The PFE stock observed a substantial rally that commenced around 2018, propelling the price to reach an apex slightly above $61.71.
Post its peak, a pronounced correction is evident, causing the stock to retreat to its current price region near $31.16.
The Fibonacci retracement levels on the chart highlight pivotal zones of potential resistance and support. As of now, the stock is oscillating near the 0.5 retracement level ($34.09).
Over the longer term, the stock has been largely range-bound, especially between 2006 to 2018, indicating regions of historical resistance and support.
The Relative Strength Index (RSI) and the Stochastic Oscillator reflect a bearish momentum with the potential for some upside, considering they are in or approaching the oversold region.

Short to Mid-Term Targets:

Immediate support appears to be at the 0.618 Fibonacci level ($29.75). Should the price maintain above this level, the immediate resistance to watch would be the 0.5 level ($34.09).
Beyond this, the 0.382 level at approximately $42.37 presents the next significant resistance.

Long-Term Perspective:

Should the stock regain bullish momentum, overcoming the historical peak around $61.71 would be crucial for setting the stage for potential new highs.
Conversely, if the downtrend continues and breaches the 0.618 level ($29.75), the stock may seek support around its previous low regions, notably close to $20.
Conclusion:
Investors are encouraged to pay heed to the evolving price dynamics and corroborate the technical indications with other relevant market news or potential catalysts. As always, considering protective measures like setting a stop-loss can aid in risk management.
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.